BRIEF published on 04/24/2025 at 14:05, 1 year 2 months ago Pentixapharm Signs Manufacturing Deal for Yttrium-90 Therapy Clinical Trials Eckert & Ziegler Radiopharmaceuticals Pentixapharm Yttrium-90
BRIEF published on 04/24/2025 at 14:05, 1 year 2 months ago Pentixapharm signe un accord de fabrication pour la thérapie à l'yttrium-90 Eckert & Ziegler Essais Cliniques Produits Radiopharmaceutiques Pentixapharm Yttrium-90
PRESS RELEASE published on 04/24/2025 at 14:00, 1 year 2 months ago Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE Pentixapharm signs manufacturing agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE to produce CXCR4-targeting radiotherapeutic doses for clinical trials Clinical Trials Eckert & Ziegler SE Pentixapharm Y90-PentixaTher Radiotherapeutic
BRIEF published on 04/15/2025 at 08:22, 1 year 2 months ago Pentixapharm Holding AG Reports 2024 Financial Results and 2025 Outlook Research And Development Financial Results 2024 2025 Financial Forecast Radiopharmaceutical Innovation Pentixapharm Strategy
BRIEF published on 04/15/2025 at 08:22, 1 year 2 months ago Pentixapharm Holding AG publie ses résultats financiers pour 2024 et ses perspectives pour 2025 Recherche Et Développement Résultats Financiers 2024 Prévisions Financières 2025 Innovation Radiopharmaceutique Stratégie Pentixapharm
PRESS RELEASE published on 04/15/2025 at 08:17, 1 year 2 months ago Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year Pentixapharm Holding AG releases 2024 financial results with EUR 12.8 million net loss and guides for EUR 23.5 million loss in 2025, focusing on R&D and operating expenses Financial Results 2024 Net Loss 2025 Pentixapharm
BRIEF published on 03/03/2025 at 14:43, 1 year 3 months ago Pentixapharm Holding AG Announces Board Changes Supervisory Board Board Changes Leadership Transition Pentixapharm Governance Dr. Andreas Eckert
BRIEF published on 03/03/2025 at 14:43, 1 year 3 months ago Pentixapharm Holding AG annonce des changements au sein de son conseil d'administration Conseil De Surveillance Transition De Direction Changements Au Sein Du Conseil D'administration Dr. Andreas Eckert Gouvernance De Pentixapharm
PRESS RELEASE published on 03/03/2025 at 14:38, 1 year 3 months ago Changes in the Supervisory Board and Management Board of Pentixapharm Holding AG Personnel changes in both the Supervisory Board and Management Board of Pentixapharm Holding AG have been implemented as of March 1, 2025, aligning the boards of the parent and subsidiary companies Supervisory Board Management Board Berlin Personnel Changes Pentixapharm Holding AG
BRIEF published on 02/13/2025 at 14:15, 1 year 4 months ago Pentixapharm to Present Pioneering Bladder Cancer Treatment at ASCO-GU 2025 Bladder Cancer Lu177-PentixaTher CXCR4 Target ASCO-GU 2025 Radioligand Therapy
Published on 06/26/2026 at 14:05, 2 hours 38 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 43 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 43 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 58 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 1 hour 13 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 19 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 20 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 21 minutes ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 07:00, 9 hours 43 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 43 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
